Results 31 to 40 of about 182,500 (270)

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study

open access: yesCancer Medicine, 2023
Pembrolizumab, an anti‐programmed death 1 monoclonal antibody, has revolutionized the treatment of metastatic urothelial carcinoma. However, the optimal treatment duration for treatment responders has not been established.
Katsuhiro Ito   +15 more
doaj   +1 more source

A Case of Stevens-Johnson Syndrome/toxic epidermal necrolysis in a patient receiving chemo-immunotherapy with pemetrexed and pembrolizumab

open access: yesCurrent Problems in Cancer: Case Reports, 2021
Chemo-immunotherapy consisting of pemetrexed and pembrolizumab is first line therapy for individuals with non-squamous non-small cell lung cancer without ALK or EGFR mutations.
Michael H. Storandt, Rishi Seth
doaj   +1 more source

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma [PDF]

open access: yes, 2022
Purpose: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study.
Chesney, Jason A; https://orcid.org/   +42 more
core   +1 more source

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

open access: yesJournal for ImmunoTherapy of Cancer, 2019
Pembrolizumab monotherapy has become the preferred treatment for patients with advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of at least 50%.
Zuan Lin
doaj   +1 more source

Unilateral Pneumonitis and Hydropneumothorax Following Pembrolizumab [PDF]

open access: yes, 2022
A man in his 80s with metastatic melanoma presented with progressive dyspnea on exertion and dry cough after 7 cycles of pembrolizumab monotherapy. He was initially treated with antibiotics for community acquired pneumonia; however, his symptoms recurred
Christine Minerowicz   +3 more
core  

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial

open access: yesLiver Cancer, 2023
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival ...
Philippe Merle   +19 more
doaj   +1 more source

Pembrolizumab-induced follicular eruption and response to isotretinoin [PDF]

open access: yes, 2022
Background: Pembrolizumab is a monoclonal antibody targeting PD-1. Folliculitis secondary to pembrolizumab has rarely been reported in the treatment of malignant melanoma.
Power, Derek G.   +3 more
core   +1 more source

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

open access: yesJournal for ImmunoTherapy of Cancer, 2019
Background Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer.
Teppei Sugano   +13 more
doaj   +1 more source

Pembrolizumab: review of its current therapeutic uses [PDF]

open access: yes, 2023
Background: Pembrolizumab is a humanized monoclonal antibody approved for human use in 2014 by the Food and Drug Administration (FDA) and in 2015 by the European Medicines Agency (EMA).
Silva, Rui   +2 more
core   +1 more source

Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation

open access: yesRespiratory Medicine Case Reports, 2019
A 66-year-old Japanese man with recurrent adenocarcinoma of the lung p-stage IIIA (pT2bN2M0; version 8) on pembrolizumab was present with gradually worsening dyspnea.
Ryo Ueno   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy